Scientists probe gut and lung bacteria to unlock bronchiectasis mysteries
NCT ID NCT05731427
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 150 adults with bronchiectasis for two years to understand how bacteria in the airways and gut influence disease progression. Researchers will also examine how macrolide antibiotics (like azithromycin) work to improve symptoms. Participants provide sputum, stool, and blood samples for advanced analysis.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Macrolides (azithromycin or clarithromycin)
- What this could lead to
- If successful, this could clarify how macrolides work in bronchiectasis and why some patients get worse, potentially guiding better treatments.
- What could go wrong
- This is an observational study with some drug treatment, not a controlled trial. It may not prove cause and effect, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2021
- Expected to finish
-
Dec 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
All patients with bronchiectasis was recruited from Wuhan Union Hospital.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria: * 18 years or older * Bronchiectasis confirmed by high-resolution computed tomographic scan(HRCT) * Chronic expectoration with ability to provide a sputum sample at the study visit * Provision of written informed consent Exclusion criteria: * Traction bronchiectasis * Lack of important clinical information
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bronchiectasis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Department of Respiratory and Critical Care Medicine, Yichang Central People's Hospital
RECRUITINGYichang, Hubei, 443000, China
-
Guizhou Provincial people's Hospital
RECRUITINGGuiyang, Guizhou, 550002, China
-
Wuhan Union Hospital
RECRUITINGWuhan, Hubei, 430022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simpler antibiotic course clear lung infections as well as a stronger one?
- A new twist on lung rehab: helping the helpers
- Gum treatment may lower lung flare-ups in bronchiectasis patients
- Can a daily pill cut dangerous lung Flare-Ups in bronchiectasis?
- Lung inflammation may speed heart aging, study investigates
- Scientists track hidden threat of antibiotic resistance in lung patients